Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Cytarabine | FIMM | pan-cancer | AAC | -0.054 | 0.7 |
mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.7 |
mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.7 |
mRNA | selumetinib:decitabine (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.011 | 0.7 |
mRNA | Nutlin-3 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.7 |
mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.7 |